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1.1 Terms and definition of multivalency 
Multivalency is an important phenomenon in various biological processes to achieve 
reversible and strong non covalent interaction between two components, i.e., ligand and 
receptor.[1] A receptor can be defined as a molecule or protein that binds to the ligand using 
the binding pocket present on their surface.[2]  
Multivalency can be divided into three categories, namely, bivalency with two 
interactions between the different species (i = 2), oligovalency (i ≤ 10) with a discrete 
number of interactions and polyvalency (i ≥ 10) with a large number of interactions 
between the two species (the exact number of which is often unknown).[2] 
Multivalency can convert inhibitors with low affinity (Kd affinity ~ mM–M) to ones with 
high avidity (Kd avidity ~ nM) and/or biological “activity”[2-3]. The affinity of a monovalent 
interaction is defined by its dissociation constant (Kd affinity); this constant usually has 
units of concentration (typically, molarity). Avidity (Kd avidity) is defined as the 
dissociation constant of a polyvalent interaction (Kd,N).  
To achieve multivalent binding, the understanding of thermodynamics of interaction i.e., 
enthalpy (ΔH) and entropy (ΔS) is very important.[4] In an ideal case the enthalpy of 
binding of a multivalent system is more favourable than that of the monovalent interaction, 
with little or no corresponding increase in the unfavourable translational and rotational 
entropy of binding. The enthalpy of interaction of a multivalent ligand with a multivalent 
receptor is, in principle, additive, while the entropy of interaction is not.[2] However in 
some cases, the binding of one ligand to a receptor with a given enthalpy may cause the 
next ligand to bind to its receptor with greater enthalpy; that is, the value of ΔHavgpoly in this 
case is more negative (more favorable) than the value of ΔHmono.[2] This can be explained 
on the basis of effective molarity (EM). Effective molarity is an important parameter and 
hence it is called the hallmark for multivalency.[5] The first binding interaction between the 
polyvalent ligand and polyvalent receptor may change concentration of ligand that will be 
experienced by the neighbouring free receptor binding site. When this so-called effective 
concentration is more than the actual concentration of ligand in solution, the intramolecular 
multivalent binding interaction are more favoured. However, when the effective 
concentration of ligand at the receptor binding site is less than that in solution then the 
binding occurs in an intermolecular manner. The effective molarity (EM) is described by 
equation (1) where Kn is the association constant for the n-valent interaction and b is a 
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Another thermodynamic term i.e., enhancement factor (β) is defined as the ratio of the 
multivalent binding constant  [Kmulti] (binding a multivalent ligand to a multivalent 
receptor) with the monovalent binding constant [Kmono] (binding of monovalent ligand to 
multivalent receptor).[3]  
 
1.2 Application of multivalency in biological and synthetic system 
Multivalent interactions are very important in various biological processes.[1b, 3, 6] As 
described above, an important function of multivalent interactions in biological systems is 
enhancing weak interactions. One example of multivalent receptor is the pentameric 
cholera toxin (CT). CT is composed of one A-subunit with a noncovalently associated 
pentameric ring of B-subunits (AB5) (Fig. 1). The B-subunits attaches to the membrane 
ligand, ganglioside GM1  at the intestinal cell surface with a high affinity and leads to the 
transport of CT into the cytoplasm, which consequently leads to the acute watery 
diarrhea.[7] This is a good system to study the design of multivalent ligands as five ligand 
can bind to CT.  
 
 
Figure 1. A) Mechanism of binding of cholera toxin to epithelial cells of the intestine. 
Adapted with permission from ref. [8] Copyright 2005 Cell Press. B) Structure of 
gangliosides GM1.[9]  
 
Another well explored example of strong lectin-carbohydrate interactions between 
polyvalent surfaces are selectins and their carbohydrate ligands. Selectin is a C-type lectin 
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like glycoproteins that mediates the rolling of leukocytes during inflammatory processes. 
The rolling of leukocyte is mediated by the interaction of multiple E- and P-selectins 
present in the endothelial cell and sialyl LewisX (sLeX), which is a tetrasaccharide ligand on 
the surface of leukocytes.[10] Also, the L-selectin which is expressed on the surface of 
leukocyte, binds to the sLeX present on endothelial cell.[11] These process leads to 
extravasation of leukocytes into the inflamed tissue, which eventually leads to severe tissue 





Figure 2. Recruitment of leukocytes to the vascular endothelium cell followed by 
extravasation of leukocytes at the inflamed tissue. Adapted with permission from ref.[1a] 
Copyright 2012 WILEY-VCH.  
 
Viral attachment to the cell surface occurs due to multivalent interaction. The binding of 
influenza virus to the epithelial cell[13]  is a very good example of multivalent interaction. 
The influenza virus attacks a target cell through multivalent interactions between multiple 
trimers of hemagglutinin (HA) with multiple components of sialic acid residues on the 
target cell surface (Fig. 3).[3, 11]  
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First application in the development of multivalent inhibitors was the synthesis of 
multivalent sialosides for binding with hemagglutinin on influenza virus.[3, 13b] These 
inhibitors were composed of linear polyacrylamide (PAA) backbone, which was 
functionalized with sialic acid (SA) residues for specifically binding with hemagglutinin on 
influenza virus. The multivalent presentation of SA on PAA inhibited hemagglutination 104 
to 105 times more strongly than did a similar concentration of methyl sialosides for 










Figure 3. Multivalent interactions of trimeric haemagglutinin (HA3) on influenza virus with 
sialic acid (SA) residues on cells leading to endocytosis and infection. Adapted with 
permission from ref.[14] Copyright 2014, Royal Society of Chemistry. 
 
CT has a low affinity with monovalent sugar and with the dissociation constants (Kd) in the 
millimolar range.[15] Hol, Fan, and co-workers explored a series of multivalent ligand 
targeting cholera toxin and heat-labile E. coli enterotoxin. They used a semi-rigid 
pentacyclen scaffold for the design of pentavalent and decavalent galatoside based 
inhibitors and observed a large enhancement in binding (105-106).[16] One of the interesting 
constructs reported by Fan and co-workers was MNPG based galactosides where five 
copies of m-nitrophenyl-α-D-galactoside abbreviated as MNPG was attached on semi-rigid 
pentacyclen core via a flexible linker. The pentameric MNPG showed 100-times greater 
inhibition than the monovalent galactose.[15b] 
Thoma et al developed a series of multivalent polylysine conjugated with sLeX to inhibit 
the E- selectin mediated cell-cell interaction. Although the monovalent sLeX had an IC50 
value in the millimolar range, the multivalent counterpart had IC50 value of 50 nM. The 
multivalent presentation of low affinity ligands showed 700-fold improved potency more 
than the monovalent ligand.[17]  
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1.3 Scaffolds for multivalent ligand 
Designing of a successful multivalent architecture requires, consideration of  not only the 
intrinsic affinity of each ligand to the receptor but also the degree of flexibility, the extent 
of hydration, and the size of scaffold.[2] The purpose of scaffold is to serve ligands attached 
by linkers to the multivalent receptor site (Fig. 4). A rigid scaffold can be used to avoid loss 
of conformational entropy upon complexation.[2] Two types of scaffolds commonly used 
for the design of multivalent ligands are randomly-coil linear polymers or spherical 
architecture (e.g., hyperbranched or dendritic polymers). The linear polymers can have high 
impact on the viscosity, whereas the spherical polymers have negligible effect on the 
viscosity of the solution.[2] Linear polymers offer flexibility and good water solubility, 
which makes it an appropriate platform for the design of multivalent ligands. The flexibility 
of the polymers can be varied using flexible or rigid backbone. Polyacrylamides (PAA) has 
been used by numerous researchers to make flexible backbone.[13] For instance, sialic acid 
(SA) functionalized PAA has been used for influenza virus inhibition.[18] Kiessling et al.  
has reported β-glucose containing linear  poly(7-oxanorbornene) polymer that was prepared 
by ROMP (ring-opening metathesis polymerization) for concanavalin A (Con A) 
binding.[19] Poly(p-phenylene ethynylene) (PPE) functionalized with mannose has been  
used for detection of E. coli by multivalent interactions. [20] Other important multivalent 
scaffold architectures are glycopolymers with different carbohydrate functionalization to 
natural architectures, for example dextrans, chitosans, hyaluronic acids and heparins.[1a] 
Sugar functionalized chitosan have been evaluated for various cell recognition studies. 
Several cell specific carbohydrates for example mannose,[21] fucose,[21b] galactose,[21b, 22] 
lactose[21a] were introduced into chitosan backbones and have been used to study the 
interaction of cells with microorganisms. Various carbohydrate functionalized dendrimers 
have been examined for the inhibition of hemagglutinin or for the binding to lectins caused 
by either bacteria or lectins. Poly(amidoamine) (PAMAM) or poly(ethylenimine) (PPI) 
based dendrimers were used as a scaffold for the multivalent presentation of ligands.[23]  
Cloninger and co-workers prepared and investigated mannose conjugated PAMAM 
dendrimers (G1 up to G6) for the Con A-induced hemagglutination inhibition of 
erythrocytes.[24] The glycodendrimers (G4-G6) with more than 50 mannose residues per 
dendrimer were efficient inhibitors of hemagglutination with significant enhancement 
because larger dendrimers were able to bind bivalently to Con A.[24b] An application of 
dendrimers as therapeutics is the poly-L-lysine (PLL) dendrimer based drug called 
VivaGel® developed by Starpharma (Australia). It is a fourth-generation dendrimer 
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(SPL7013) covered with naphthalene disulfonate, which is believed to bind with the virus 
by electrostatic interactions and thus preventing its attachment to the host cells. This 
polymer is currently under clinical development as a topical vaginal gel to prevent the 












Figure 4. Structures of commonly used scaffolds for the multivalent display of ligand. 
 
1.4 Polyglycerol based scaffolds 
Polyglycerols polymers are a potent class of scaffold for the multivalent display of ligands, 
because of their good water solubility, biocompatibility, low toxicity, high number of 
hydrophilic functional groups, and a highly flexible aliphatic polyether backbone. [13b, 26] 
Kim and Webster were the first ones to introduce the term “hyperbranched polymers” in 
1980 to define dendritic macromolecules synthesized by ABm-type polycondensation.[27] 
Unlike most dendrimers, which are prepared in multistep syntheses, hyperbranched 
polymers can be synthesized in single step and are considered the “poor cousins of 
dendrimers” because of their high polydispersity.[28] Hyperbranched polymers do not show 
entanglements, due to which they have very low bulk viscosities in comparison to linear 
polymers. Molecular weight (M.Wt.), degree of branching (DB), and polydispersity (PDI) 
are the three fundamental parameters to characterize the hyperbranched polymers. Control 
of these parameters are essential for the development of complex macromolecular 
architectures. [28a] 
Polyglycerols can be produced by various polymerization methods.  Kim and Webster 
reported the synthesis of hyperbranched polymers by the most common method i.e., 
polycondensation of ABm type monomers, which strongly affects the DB and molecular 
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weight distribution of the polymer.[27a] A second method, reported by Fréchet and co-
workers used self-condensing vinyl polymerization (SCVP), where the vinyl monomer 
bearing an initiating group was used.[29] The disadvantages of using these methods were 
that the obtained polymers have broad molecular weight distribution and very high PDI. A 
third method reported by Sunder et al in 1999 is the ring opening multibranching 
polymerization (ROMBP) where cyclic AB2-type monomers were used.[30] This type of 
polymerization was carried out by anionic ring opening polymerization of commercially 
available glycidol by making use of partially deprotonated trifunctional core-initiator. In 
this method, hPG was synthesized in a one-step process starting with a slow addition of 
glycidol to partially deprotonated trimethylolpropane (TMP). Due to fast polymer exchange 
that occurs during polymerization the different chain ends (primary and secondary alcohols) 
grow simultaneously, which gives rise to a branched structure (Fig. 5). The molecular 
weight of polymers obtained by this method, which can be adjusted by the ratio of 
monomer to initiator and PDI, is typically low. Brooks et al reported similar 
biocompatibility profiles of hPG and polyethylene glycol (PEG).[31] However, hPG has 
slightly higher thermal and oxidative stability in comparison to PEG.[26b, 31-32] Considering 
these remarkable features, hyperbranched PGs is a suitable material for biomedical 
applications.  
As described above, polymerization of glycidol leads to the formation of hPG, but linear 
polyglycerol (LPG) can also be obtained, when the protected glycidol is used as a monomer 
followed by removal of the protective group in the post polymerization step (Fig. 5). 
Typical monomers used for the LPG synthesis  are trimethylsilyl glycidyl ether (TMSGE), 
ethoxyethyl glycidyl ether (EEGE), tert-butyl glycidyl ether (tBGE), and allyl glycidyl 
ether (AGE).[33] EEGE is the most commonly used for the synthesis of LPG due to easy 
removal of acetal protecting group under mild acidic condition.[33] Typical low molecular 
weight PGs are obtained with initiators such as potassium tert-butoxide (t-BuOK),[34] 
potassium 3-phenylpropanolate (PPOK),[35] alkoxy ethanolates and potassium methoxide 
(MeOK)[36]. Taton et al was the first one to report the synthesis of LPG by anionic ring-
opening polymerization of EEGE using CsOH as an initiator with high molecular weight 
(approx. 30kDa).[37] Typically, anionic polymerization of protected glycidol like EEGE is 
carried out using an initiator which leads to the formation of protected LPG. Tetraoctyl 
ammoniumbromide (NOct4Br) could be used as initiators and triisobutylaluminum (iBu3Al) 
for the activation of monomer as reported previously in the literature.[38] In the second step, 
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acetal protection is removed by acid-catalyzed reaction which leads to the formation of 






















2. Lectin binding by multivalent glycoconjugates 
2.1 Influenza virus and hemagglutinin 
The influenza viruses belongs to the class of Orthomyxoviridae family of viruses and it is 
characterized by single-stranded RNA genome of negative polarity, which is contained 
within an enveloped virion as eight different RNA segments.[39] There are four types of 
influenza virus namely A, B, C and D.[40] The influenza A viruses are responsible for major 
pandemics that mostly cause higher mortality rates than seasonal influenza epidemics. In 
the last century, influenza A viruses have caused four major pandemics, the most severe 
one was 1918 Spanish pandemic which caused approximately 40 million death 
worldwide.[41] The other three pandemic includes 1957 Asian pandemic, 1968 Hong Kong 
pandemic, and the 2009 H1N1 pandemic.[42] The H5N1 virus (bird flu) that was first 
detected in Hong Kong in 1997 has been reported to cause serious human disease and 
caused high mortality rate.[42d] In contrast, the 2009 H1N1 virus (swine flu) was able to do 
human-to-human transmission but was a relatively milder disease with a lower mortality 
rate.[43] The virion envelope of influenza A viruses are decorated with two major surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), as well as integral membrane 
protein (M2 ion channel protein) (Fig. 6).[44] Influenza A viruses are divided into subtypes 
based on antigenic HA and NA subtypes i.e., 18 HA (H1-H16) and 11 NA (N1-N9) 
antigenic subtypes have been found to circulate so far.[45] The major subtypes of influenza 
A that have affected human population during seasonal epidemics are H1N1, H2N2, and 
H3N2.[40b, 42d] HA molecules mediate the attachment of virus to sialylated glycan receptors 
on the host cells, and thus release the viral ribonucleoprotein particles into the cytoplasm. 
NA catalyzes the cleavage of the glycosidic bond of terminal sialic acid on the host surface 
and facilitates the release of the virion (Fig. 6).[46]  
Influenza A viruses undergo constant evolution through mutation of virus itself and re-
assortment of viral genomes from different strains.[47] It undergoes constant point mutation 
at antigenic sites over time as the virus replicates. These are called antigenic drift. These 
genetic changes can occur at the surface protein of influenza A virus (IAV) such as HA or 
NA. As a consequence, the body’s immune system are unable to recognize those viruses 
and the immune protection will  no longer be effective against virus which will cause viral  
infection.[48] The exchange of genetic material between coinfecting viruses that is called 
reassortment, is another process by which influenza virus undergoes evolution.[49] The 




















Figure 6.  Schematic diagram showing the viral replication process. Adapted with 
permission from ref.[50] Copyright 2007 Nature Publishing Group. 
  
Influenza virus has eight different segments of virus, the reassortment of virus leads to new 
antigenic pattern called antigenic shift.[51] It is a special case of reassortment. As described 
above, antigenic drift is natural mutation over a long period of time which causes loss of 
immunity contrasts with antigenic shift. Antigenic drift occurs in influenza A, B and C 
whereas antigenic shift occurs only in influenza A virus. Two of the major pandemics in 
20th century, i.e., 1957 and 1968 pandemic flue, emerged due to reassortment between 
human IAV and avian influenza virus, [47a, 52] whereas 2009 swine flu outbreak was due to 
reassortment of human, swine, and avian influenza virus.[47a] Other than mutation and 
reassortment, IAVs can undergo mutation by relatively rare means called 
recombination.[47a] Recombination occurs through two mechanisms, one is non homologous 
recombination, which happens between two different RNA fragments.[53] The other method 
of recombination known as homologous recombination in influenza virus. It involves in 
template switching of RNA molecules that coinfect a single cell. Homologues RNA 
recombination rarely occurs.[54] Due to these genetic drifts of influenza virus there is urgent 
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need for development of new vaccine and drugs production against seasonal influenza 
viruses each year.[55] 
As hemagglutinin is the major surface antigen of influenza A viruses, it is primary source 
of natural immunity and key target in vaccination. It plays an important role in the 
development of human pandemic influenza viruses.[55] HA exists as a trimer of identical 
subunits, and has a cylindrical shape with approximate length of 135 Å and radius of 35-70 
Å.[56] It is present as spike-like protein on the surface of influenza virus. Each monomer of 
HA molecule contains a globular head domain and a stem domain. The receptor binding 
site is located on globular domain.[57] The receptor for influenza virus spikes i.e., HA is 
sialic acid (SA) containing molecules on the cell’s surface.[44, 58]  However, there are a 
number of chemically different forms of sialic acids, which are based on glyosidic linkage 
of SA and the next sugar of the side chain, the influenza virus varies in its affinity for 
SA.[44] The human IAVs (e.g., H3N2) prefer to bind sialic acid with α2,6-glycosidic linkage 
to galactose.[59] Whereas, viruses of avian origin (e.g., H5N1) preferentially binds to SA 
with α2,3 glyosidic linkage to galactose.[60] Neuraminidase (NA) is another major 
membrane protein which is embedded on the surface of influenza virus.[61] It exists as a 
mushroom-shaped tetramer of identical subunits and it extends approximately 60 Å from 
the surface of the virus. NA is an enzyme that catalyzes the hydrolysis of glyosidic bond 
during the process of viral replication, specifically terminally linked sialic acid from 
glycoprotein saccharide chains and removes SA from the cellular glycoproteins. As a result, 
the virus is released from the membrane and move off to infect other cells and spread the 
infection.[62] 
Currently, two different strategies are used to control the spread of influenza virus namely, 
vaccines and small molecule based antiviral drugs. Vaccines are in the first line of defense 
against influenza, however, production of sufficient quantities of vaccine with appropriate 
antigens takes 6 months, therefore antiviral drugs are  important countermeasure to reduce 
the effect of influenza virus infection.[63] Two classes of anti influenza drugs are currently 
available to treat influenza infections i.e., M2 ion channel inhibitors (amantadine and 
rimantadine) and neuraminidase inhibitors (NAIs: oseltamivir, zanamivir, peramivir, and 
laninamivir). The M2 ion channel inhibitors block the influx of protons through M2-proton 
channel so that uncoating and release of genetic material into the cytoplasm are inhibited. 
NAIs block the sialidase, and hence inhibit the release mechanism of virus. However, IAV 
rapidly developed resistance against these classes of drugs due to mutation of viral 
components. Most of the circulating IAV has developed resistance for M2 ion channel 
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inhibitors.[45c, 64] Thus, NAIs are the only remaining class of drugs to prevent influenza A 
and B virus infection. Hence development of new anti-IAVs drug is very important to 
protect the population against influenza virus. 
An alternative approach for the prevention of influenza virus infection is to target HA 
which mediates the entry process.[65] The inhibition of HA will block the initial step of viral 
infection.[66] Until now, various types of anti-influenza compound targeting HA have been 
reported, including small molecules, monoclonal antibodies, peptides and proteins.[67] The 
crystal structure of HA reported by Wiley and co-workers has led to an extensive search for 
small molecules that can bind to HA with high affinity.[68] No compound targeting HA has 
been reported as a drug yet.[44, 69] This is mainly due to weak interaction of HA to its natural 
ligand SA.[70] Also the binding affinity of HA with monovalent SA is very weak (10-3 M) 
and it requires high concentration of monovalent SA.[70] Several polymeric multivalent 
sialosides have been reported in the literature, which show strong binding to HA.[71] 
Whitesides and co-workers have reported a series of polyacrylamides presenting α-C-
glycosidic Neu5Ac group as a side chain for the inhibition of IAV. The best copolymer 
inhibited HA approximately 104-105 times more strongly than did a similar concentration of 
α- methyl sialoside.[13a] Although high molecular weight PAA polymer based sialosides 
reported by Whiteside’s group were extremely effective against virus, but due to toxicity of 
PAA based material, various other synthetic scaffolds continue to be investigated.[18] A 
variety of multivalent polymers functionalized with sialic acid have been reported in 
literature which show more enhancement in binding affinity than its monovalent 
counterpart.[13a, 71-72] As mentioned before, commercially available dendrimers such as 
PAMAM related scaffolds have been explored for multivalent display of sugars.[23] Kwon 
and co-workers reported the importance of optimal ligand density and spacing between the 
ligand for the design of effective IAV inhibition. They used spherical PAMAM scaffold 
and decorated with 6'-sialyllactose (6SL) to prepare a series of multivalent IAV inhibitors. 
The most potent candidate among the series was G4 based 6SL-PAMAM conjugates with 
dissociation constant of 1.6 × 10−7 M. In vivo application of these conjugates protected 75% 
of mice from H1N1 and successfully prevented the loss of weight for infected animals.[73]   
Recently, Bhatia and co-workers reported the importance of architecture and optimal ligand 
densities for the development of multivalent IAV inhibitors. PGs (LPG and dPG) were used 
as scaffolds for the multivalent display of SA and LPGSA with 40% ligand density was the 
most potent candidate with a dissociation constant in low micromolar range (Fig. 8A). 
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Also, in vivo application of LPGSA and NAI i.e., oseltamivir carboxylate showed 
synergistic inhibitory effect and efficiently prevented IAV infection.[26c]  
Papp et al, investigated synthesized dendritic polyglycerol based nanogels (nPG) and 
functionalized it with sialic acid with diameters in the range of 25-100 nm for influenza 
virus inhibition (Fig. 8B). The ligand density and size of nanoparticles were optimized, and 
they found that larger particle i.e., 50 nm sized nPG with 12% ligand density was the most 
potent candidate showed up to 80% inhibition of viral activity (IAV/X31) at low 
micromolar concentration .[74] Also, glycerol based dendrons (1 nm) were functionalized 
with sialic acid and were covalently attached to gold based nanoparticles (AuNPs) in 
different size range (2 nm and 14 nm). The sialylated AuNPs with a 14 nm size were highly 
efficient for the inhibition of influenza virus, whereas, the 2 nm AuNPs did not have any 
significant impact on inhibition of influenza virus. This work highlighted the importance of 
matching particle size for efficient infection inhibition.[26d] 
In this direction, Lauster et al developed a new class of polyglycerol-based peptide 
conjugates for the inhibition of IAV (Fig. 8C). In this study they used two types of peptide 
which binds to CRD domain of HA namely PeB and PeBGF to synthesize a series of 
multivalent polyglycerol-based peptide with different molecular weight of PG-scaffold. 
They found that PG-PeBGF conjugates had higher affinity in comparison to PG-PeB based 
construct when tested for in vitro assay i.e., in HAI and MST based experiment. In contrast, 
PG-PeB conjugates was more potent as multivalent inhibitor for in vivo model.[75] 
Typically, HA is uniformly distributed on the surface of influenza virus having 
approximately 400-500 copies of HA trimer. The Cryo-TEM imaging suggested 4-5 nm  
average distance between the binding site on single HA trimer, however a 10-12 nm 
distance between the midpoints of two adjacent HA trimers (Fig. 7).[76] Design of 
multivalent sialosides with an optimal spacing in between the ligands to target 
hemagglutinin trimeric glycoprotein with high affinity has also been explored using 











Figure 7.  Schematic diagram showing A) Cryo-TEM image of human IAV (X31/H3N2) 
presenting the HA trimer. Adapted with permission from ref.[76a] Copyright 2016 American 
Chemical Society. B) The average distance between the receptor binding site of two 
adjacent HA trimer and inter-trimeric distance.  Adapted with permission from ref.[76b] 
Copyright 2017 American Chemical Society. 
 
Waldman and co-workers reported trivalent SA decorated glycopeptide conjugates to target 
HA trimer of IAV (Fig. 9B). To reduce the overall flexibility of trivalent sialosides and 
minimize the entropic cost required during binding, they chose conformationally stiff 
peptide-based spacers instead commonly used ethylene glycol oligomers. The best tripodal 
compound had low nanomolar binding affinity (Kd = 450 nM) against H5 of avian influenza 
which was 4000-fold higher in comparison with monovalent Neu5Acα2Me. Thus they 
obtained the interaction strength between bi- (500-fold) and trivalent (300 000-fold) 
ligands.[69] Ohta and co-workers reported cyclic peptide based scaffold for the trivalent 
presentation of sialyllactose [Neu5Acα(2,3)Galβ(1,4)Glc] to target trimeric HA protein 
(Fig. 9C). The highest affinity glycopeptide based inhibitor were obtained when all the 
three ligands were pointing outward from the cyclic peptide ring so that 3 sugar can reach 
the binding pockets of HA trimer simultaneously to have multivalent effect (Kd = 0.65 
mM).[77]  
Bandlow et al, explored two different type of scaffold namely flexible PEG based and rigid 
self-assembled DNA.PNA based scaffold for the bivalent display of α2,6-linked 
sialyllactose (Sialy-LacNAc) ligand at distance of 23-101 Å to target the HA trimer of 
IAV/X31 (Fig. 9A). They investigated that although the end to end distance of ligand was 
50 Å for the PEG based construct which should be ideally suitable to bridge the distance of 
receptor binding site on HA but due to flexible nature of PEG based scaffold, effective 
concentration of ligand at the second binding site was significantly much lower (100 µM) 
than the binding affinity of monovalent ligand (Kd = 3 mM). However, DNA based 
construct having end to end distance in the similar range (52 Å) as that of PEG spacer, it 
had 100-times more effective concentration in comparison to PEG based construct. This 
shows the bimodal relationship of distance-affinity for the interaction with HA IAV with 
Sialy-LacNAc ligand DNA.PNA based scaffold.[76b] 
These examples suggest that the use of conformationally stiff peptide-based spacers for the 
design of multivalent inhibitors would be a good choice to attain a high affinity multivalent 
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inhibitor due to minimal loss in conformational and rotational entropy up on binding with 
receptor.[76a, 78] Yamabe and co-worker also focused on the spatial arrangement of SA 
binding sites and designed 2,3-SL functionalized three-way junction (3WJ) DNA 
architecture where topology of the inhibitor was like the SA binding sites. The best 
candidate was 3WJ DNA with three 2,3-SL and it has 8.0 ×104-fold higher binding affinity 





Figure 8. Polyglycerol based sialosides synthesized by A) Bhatial et al.[26c] B) Papp et al. 
[74] C) Lauster et al.[75] Architecture B) adapted with permission from ref.[76a] Copyright 













Figure 9. Different peptide based scaffold for HA trimer of influenza virus A) divalent 
DNA.PNA based sialyllactosides reported by Bandlow et al.[76b], B) trivalent peptide based 
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sialosides reported by Waldman et al.[69] and C) cyclicglycopetide based trivalent sialosides 
reported by Ohta et al.[77] 
 
2.2 C-type lectins 
The C-type lectins (CTL) were amidst the first animal lectins recognized and approximately 
more than 1000 proteins were found to have C-type lectin-like domains (CTLDs).[80] 
Originally the C-type designation for these molecules originates from their dependence on 
Ca++ for sugar binding through their conserved residues within CTLD.[81] The carbohydrate 
binding activity of CTLs is mediated by a highly conserved module called carbohydrate 
recognition domain (CRD). However, the CTLDs of many C-type lectins is not 
compulsorily restricted to bind carbohydrates or Ca++. CTLs and proteins with CTLD are 
present in all organisms. Based on the organization of domain, CTLDs are divided into 17 
groups.[80, 82] In mammals CTLs are divided into two types based on the molecular structure 
of C-type lectin receptors (CLRs) i.e., transmembrane proteins and soluble proteins (Fig. 
10A). For example, DC-SIGN belongs to the class of transmembrane protein and MBL 
belongs to the class of soluble protein which will be discussed in the next section. These 
proteins usually oligomerize into homodimers, homotrimers, and higher order of oligomers, 
which enhance their binding ability for multivalent ligands.[83] However, all the CTLDs 
have similar structural homology still they have different specificity for binding the 
different type of carbohydrates. CTLs have diverse functionality including cell adhesion 
and as a signaling receptor for various immune function such as pathogen recognition and 
inflammation.[84]   
The structural analysis of C-type carbohydrate recognition using mannose binding proteins 
(MBP) of serum showed that CRD of CTLs have a hydrophobic core and disulfide bonds 
that represent the overall characteristic of domain.[85] C-type CRD of MBPs bind to several 
different sugars containing adjacent equatorial hydroxyl group like hydroxyl group at 3 and 
4 positions of mannose, glucose, fucose, N-acetylglucosamine (GlcNAc) due to presence of 
EPN (Glu-Pro-Asn) motif where 3 and 4 hydroxyl groups of sugar directly coordinate with 
Ca++ and form H-bond. In addition to this, it also binds with galactose-type sugars where 4 
hydroxyl group is at axial position such as galactose and N-acetylgalactosamine (GlaNAc) 


















Figure 10. A) Diagram showing the different types of C-type lectin receptor.[87] and B) 
Binding of sLeX  at CRD of MBL-A. White, black, small grey and large grey spheres are 
representing carbon, oxygen, nitrogen, and calcium, respectively. Coordination bonds are 
shown as thick dashed lines, and H-bonds as thin dashed line. Adapted with permission 
from ref.[88] Copyright 1997 Elsevier Ltd. 
 
2.2.1 MBL 
Mannose binding lectin or mannan binding lectin (MBL) is a member of collectin family 
which plays an important role in innate immune system.[89] MBL has a bouquet like 
structure and exist in various oligomeric forms ranging from dimers to hexamers. These 
oligomers are built of subunits that consist of three identical peptide chains of about 32 kDa 
each. Each chain is made up of a cysteine rich N terminal,  collagen-like domain, a 
hydrophobic neck region and a Ca++-dependent carbohydrate recognition domain (CRD).[90] 
The collagenous domain of three polypeptides chains are held together by disulfide bonds 
to form triple helical structure (Fig. 11A).[91] The MBL carry two calcium ions, named as 
sites 1 and 2.[92] The calcium ion at site 2 form coordination bonds with the 3 and 4 OH 
group of “mannose type” sugar as mentioned in the previous section. The hydroxyl group 
has 2 lone pairs of electrons and 1 proton free for non-covalent interactions. One of the two 
lone pair of electrons of OH group is utilized in forming coordination bond with calcium 
ion and the other tend to form H-bond acceptor for amine functionality of two asparagine 
(Asn) residues. The Asn residue uses its free oxygen to form coordination bond with 
calcium ion. The proton is involved in forming the H-bond with carboxyl group of the side 
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chain. Thus, it gives pentagonal bipyramidal geometry (Fig. 10B). However, when there is 
no sugar available for binding, these positions are occupied by water molecules, showing 
that these water molecules are displaced upon carbohydrate binding.[86a] Due to 
hydrophobic interface between neck and carboxyl terminal pf CRD, the distance between 
receptor binding site is 45 Å (human) and 53 Å (rat) in the trimer.[86c, 90a] 
MBL has been known to bind with a wide range of pathogens including bacteria, viruses 
(e.g., HIV, HSV, IAV)  yeasts (C. albicans), fungi and protozoa decorated with 
carbohydrates molecules.[93] MBL binds to various mannose type carbohydrate moieties 
specifically mannose, fucose, glucose, N-acetyl-D-glucosamine, and N-acetyl-
mannosamine.[94] Selectivity of human MBL (hMBL) for these sugars binding is N-acetyl-
D-glucosamine > mannose > N-acetyl-mannosamine and fucose > glucose.[95] MBL is 
involved in the activation of lectin complement pathway (will be discussed in next section) 
and enhancement of opsonophagocytosis.[96] It is also shown to be involved in the 
promotion of apoptosis and regulation of inflammation.[90a]  
 
2.3.1 MBL and complement system 
Complement system is a part of innate immune system.[89, 95, 97] It consists of many plasma 
proteins which interact with one another to opsonize the microorganisms and induce a 
cascade of inflammatory reaction that support the host to combat the infection. There are 
three pathways of complement activation: classical pathway, alternate pathway and 
mannose binding lectin pathway (MBL pathway).[98]  The classical pathway is triggered 
upon direct binding of a protein complex known as the complement component 1q (C1q), 
to the surface of microorganism.[99] The second pathway i.e., alternative pathway is 
activated when a spontaneously activated complement component attaches to the microbial 
surface.[98] 
The MBL pathway  is activated upon binding upon MBL binding sugar rich pathogen 
surface.[100] A family of two serine protease: mannan-binding lectin- associated serine 
protease (MASPs) namely MASP-1, MASP-2 and MASP-3 are reported to be associated 
with MBL. Furthermore, a small molecular weight (19 kDa) protein called small MBL-
associated protein (sMAP) or MBL-associated protein of 19 kDa (MAp19) are also found 
in the complex. When the MBL complex attaches to the surface of pathogen, it leads to the 
activation of MASP-1 and MASP-2 which further cleave the blood protein C4 (C4a and 
C4b) and C2 (C2a and C2b). The C4b then attaches to the pathogen surface forming the 
complex with C2b and initiate the formation of C3-convertase. The subsequent complete 
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cascade mediated by C3-convertage leads to the formation of membrane attack complex 
(MAC), which results in the formation of pore in the lipid bilayer membrane that disrupt 
the integrity of membrane. This ultimately kills the pathogens by destroying the H+-
gradient across the cell membrane of pathogen (Fig. 11B). [101] 
There are 3 different ways by which the complement system safeguard against the 
microbial infection. First, opsonization of pathogens. In this process, the activated 
complement proteins attach covalently to the surface of microbes and it can be then 
recognized by phagocyte bearing receptor that signal for phagocytosis. Second method 
utilizes the complement proteins to act as chemoattractant which leads to the recruitment of 
more phagocytes at the site of complement activation which further causes phagocytosis. 
Third, the MAC or terminal complement complex (TCC) is formed on the surface of 
pathogen which create pores on the cell membrane of microbes leading to cell lysis and 
death of pathogens.[102] 
Although MBL has important role for the protection against pathogen infection, an excess 
of MBL activation could be injurious, because of an uneven proinflammatory response 
causing additional tissue damage.[103] High level of MBL activity have demonstrated 
inflammatory autoimmune diseases like Systemic Lupus Erythematosus, causing organ 
damage. Moreover, increased level of MBL serum concentration and complement activity 
is responsible for transplant rejection, myocardial reperfusion ischemic injury, diabetic 
nephropathy, cerebral ischemia injury, traumatic brain injury (TBI) and other cellular 
injury.[104] Thus, high level of MBL activation contribute to tissue damage and hence 










Figure 11. A) Structure of the MBL oligomer, and B) mechanism of complement activation 





2.2.1.2 Inhibitors for MBL pathway 
Many reports showing the therapeutic benefits of using inhibitors to reduce the activation of 
the complement pathway has been demonstrated in the literature. For example, recombinant 
soluble complement receptor type-1 (sCR1) has been shown to decrease the infract volume 
by more than 40%.[105] Furthermore, during the clinical trial, sCR1 was given to the patients 
suffering myocardial ischemia (MI), resulted in the recovery from ischemic contractile 
failure of the heart.[106] Moreover, monoclonal antibodies (mAbs) were designed to inhibit 
the complement cascade at C5 or C5a and C1 esterase inhibitor (C1-INH) for the inhibition 
of the complement system to avoid spontaneous activation have been shown in literature to 
decrease injury, improved organ function IR raised the survival rate in various animal 
model for human disease.[107] 
There are large number of proteins and antibodies for the inhibitory effect against various 
complement components have been documented in the literature. Jordan et al demonstrated 
the use of mAbs (P7E4) for the inhibition of C3 deposition in heart during MBL pathway, 
which further reduced the infarct size and tissue injury, neutrophil accumulation, 
proinflammatory gene expression (e.g., ICAM-1, IL-6, and VCAM-1).[108] Pavlov et al 
designed a novel mouse model expressing hMBL and showed that mAbs 3F8 prevented the 
deposition of C3 and further decreases infarct size and inhibit thrombogenesis. Additional 
inhibitors for MBL complex have been designed and used in IR models.[109] Natural, 
endogenous inhibitor namely MBL/ficolin -associated protein-1 (MAP-1), when used at 
pharmacological doses removes MASP-1, -2 and -3 from MBL complex and inhibit lectin 
pathway activation and prevent myocardial dysfunction in mice having MI/R.[110] Not much 
has been reported on synthetic inhibitors against MBL pathway so far. Orsini et al has 
reported Polyman2, a dendritic system with multivalent display of mannose residue which 
has effectively reduced the infarct volumes during cerebral injury.[111] Similar dendritic 
mannosides were explored by Blasio et al for the inhibition of MBL pathway showing a 
dose dependent inhibition of rhMBL for example Polyman2 has IC50 = 270 µM, Polyman9 






















Figure 12. Structures of the glycodendrons reported by Stravalaci for MBL binding: 
Polyman2, Polyman9, and Polyman31.[112b] 
 
2.2.2 DC-SIGN  
DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) 
is a C-type lectin receptor and belongs to the class of type II integral membrane protein and 
it is involved in both innate and adaptive immune system. It binds to the sugar in a calcium 
dependent fashion and serves as a cellular adhesion receptor and is involved in binding with 
a wide spectrum of microorganisms.[113] For example, DC-SIGN bind to viruses (Ebola 
virus, hepatitis C virus, Dengue virus, HIV-1, HIV-2 and SARS coronavirus), bacteria 
(Mycobacterium tuberculosis and Helicobacter pylori), and parasites (Leishmania and 
Schistosoma).[114] 
DC-SIGN consist of three structurally distinct domains: a cytosolic tail domain, a 
transmembrane segment, and an extended extracellular domain (ECD) which project the 
CRD region up to 320 Å above the cell membrane so that it can interact with pathogens.[115] 
The ECD is further divided into two structurally and functionally distinct domains: the neck 
repeat region, which play very important role in the formation of tetramers of the receptors 
and the carbohydrate recognition domain (CRD) which facilitate the binding of microbes in 
a calcium-dependent fashion (Fig. 13A).[116] The CRD in DC-SIGN interacts with two 
classes of glycans: N-linked highly mannosylated oligosaccharides such as 
(Man)9(GlcNAc)2, which is a branched oligosachharide that is available in multiple copies 
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on the surface of several pathogen and specifically on gp120 envelop protein of HIV (Fig. 
13B). DC-SIGN also interact with branched, fucosylated oligosaccharides having terminal 
fucose unit, for instance Lewis antigens.[117] High mannosylated glycans are present on 
various enveloped viruses such as HIV, however fucosylated glycans are commonly present 
on parasites.[118] The oligosaccharide’s binding with DC-SIGN occurs by coordination of 
residual sugars of oligosaccharides to the calcium binding site present on the surface of 
protein as mentioned before. In addition to promoting the infection process, DC-SIGN 
plays an important role in immunoregulation process that have attracted the attention of 











Figure 13. A) Structure of DC-SIGN showing Ca++ dependent CRD domain, a neck region, 
a transmembrane region and cytoplasmic tail, and B) Tetramerization of DC-SIGN and 
further clustering which allow high binding avidity which influences pathogen binding 
(e.g., HIV-1 binding).[120] 
 
Since CRD of DC SIGN receptors is exploited by large number of highly opportunistic 
pathogens and cause infection to the host cell. Therefore, development of anti-infective 
agents for DC SIGN is extremely important.[119] 
The binding of monosaccharides with the CRD of DC SIGN are very weak i.e., Ki (L-
fucose) = 6.7 mM and Ki (D-mannose) = 13.1 mM being the highest binding amongst 
monosaccharides. [121] To overcome this, several multivalent carbohydrate architectures 
have been reported in literature. Rojo et al were the first one to report the multivalent 
glycoconjugates against DC-SIGN. They synthesized G3 Boltron-type dendrimers for the 
multivalent presentation of 32 copies of mannose and found that it strongly inhibited the 
DC-SIGN facilitated Ebola pseudo typed virus infection at very low concentration, with 
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IC50 = 337 nM. But the relatively long synthesis and instability of the scaffold were strong 
drawbacks of this synthetic approach.[122] 
Recently Becer et al have synthesized a library of glycoconjugate decorated with different 
ratio of mannose and galactose to investigate the binding inhibition of DC-SIGN to gp120 
glycoprotein. The glycoconjugate with 100% mannose was most potent candidate with IC50 
value of 37 nM which is 40 times better affinity in comparison to mannose.[123] 
Sattin et al designed tetravalent construct displaying 4 copies of pseudo-trimannoside which 
inhibited HIV-1 transfection to CD4+ T lymphocytes with approximately >94% inhibition 
at 100 µM concentration. The tetrameric dendron having four unit of D-mannose were 
tested for the purpose of comparison, and they found that the control molecule failed to 
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3 Motivation and Objective 
Seasonal influenza is the major cause of human death worldwide every year. Developing 
new class of antiviral drugs is essential because of high mutation rate and increased 
resistance of influenza strains against available drugs. An approach to develop high affinity 
inhibitors of influenza virus is optimizing trivalent sialosides to target three receptor 
binding sites on the hemagglutinin trimers and thus efficiently inhibiting virus -cell 
attachment during the initial stage of infections. Several trivalent sialosides have been 
explored previously to target HA trimers of influenza virus. But selection of the 
architecture and the linker is associated with disadvantages, for example, protein-based 
ligands can have autoimmune response inside the body and the peptide-based ligand is 
associated with the stability issue at biological pH. Scale of such constructs for advanced 
therapeutic use is also tedious.  
Our objective in the first part of this thesis is optimizing trivalent synthetic architecture 
using OEG spacer to target HA trimer of IAV/X31. The OEG spacer will be used as a 
linker because of their biocompatibility and good water solubility. We will use 
functionalisable   rigid and flexible core which has the possibility to attach trivalent ligands 
with the large scaffolds to afford multimeric presentation of ligands for influenza inhibition. 
We will synthesize tripodal architecture with rigid and flexible core on which monomeric 
ligand i.e. SA will be attached to target the HA trimer. The adamantane core will be 
considered as rigid core due to restriction in the degree of freedom and the commercially 
available and highly economic 4-(((benzyloxy)carbonyl) amino)-4-(2-carboxyethly) 
heptanedioic acid abbreviated as Tris will be used as a flexible core. MD simulation data 
will be used to determine the length of OEG spacer to bridge the distance between receptor 
binding site on HA trimer and the core of scaffold. Labelled microscale thermophoresis 
(MST) will be used to study the binding affinity of trivalent sialosides with the IAV-X31. 
Rhodamine (R18) will be used to label the intact X31 virus. To analyse the effect of 
valency (2 vs 3 SA) on affinity value, a divalent adamantane based sialosides shall be 
synthesized using the similar procedure as described for trivalent system. 
C-type lectin inhibitors are therapeutically interesting for several biomedical applications. 
In the second part of thesis, our objective is to design biocompatible and water-soluble 
polyglycerol based multivalent glycoconjugates to target two very interesting class of C-
type lectin namely MBL and DC-SIGN. They bind to various carbohydrates specially 
mannose type ligand having equatorial hydroxyl group at 3 and 4 position presents on 
various microorganism and are involved in various infectious process. So far, mostly 
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branched architectures have been implied for lection binding. Here we will compare linear 
and branched architectures with chemical structure and linkage. Herein, we will use linear 
and hyperbranched PG based scaffolds for multivalent display of mannose and 
fucosyllactose. Carbohydrates will be assembled on PGs using very simple and easy, 
copper copper-assisted click chemistry between alkyne-functionalized PGs and azide-
functionalized sugar molecules. To analyze the size of glycoconjugates, dynamic light 
scattering (DLS) technique shall be used. Further on, the degree of functionalization be 
determined by NMR spectroscopy and CHN elemental data. Surface plasmon resonance 
(SPR) binding analysis and non-labelled MST techniques will be used to study molecular 
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4 Publication and manuscript 
In the following section the published article and submitted manuscript are listed and the 
contributions of the author are specified. 
4.1 Exploring Rigid and Flexible Core Trivalent Sialosides for Influenza 
Virus Inhibition 
Pallavi Kiran,[+] Sumati Bhatia,[+] Daniel Lauster, Stevan Aleksić, Carsten Fleck, Natalija 
Peric, Wolfgang Maison, Susanne Liese, Bettina G. Keller, Andreas Herrmann, Rainer 
Haag* Chem. Eur. J. 2018, 24, 1–14.[124]  
[+] authors contributed equally. 
https://doi.org/10.1002/chem.201804826 
Abstract 
Herein, the chemical synthesis and binding analysis of functionalisable rigid and flexible 
core trivalent sialosides bearing oligoethylene glycol (OEG) spacers interacting with spike 
proteins of influenza A virus (IAV) X31 is described. Although the flexible Tris- based 
trivalent sialosides achieved micromolar binding constants, a trivalent binder based on a 
rigid adamantane core dominated flexible tripodal compounds with micromolar binding and 








Figure 14. Adapted with permission from Kiran et al.[124] Copywrite 2018 Wiley- VCH Verlag GmbH & Co. 
KGaA, Weinheim. 
 
Author’s contributions: In this publication the author contributed to the synthesis, 
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4.2 Synthesis and comparison of linear and hyperbranched multivalent 
glycosides for C-type lectin binding 
Pallavi Kiran, Shalini Kumari, Jens Dernedde, Sumati Bhatia*, Rainer Haag* to be 
submitted. 
[P. Kiran, S. Kumari, J. Dernedde, R. Haag and S. Bhatia, New J. Chem.,2019.] - 
Reproduced by permission of The Royal Society of Chemistry (RSC) on behalf of the 
Centre National de la Recherche Scientifique (CNRS) and the RSCCopyright (2019) New 
Journal of Chemistry. 
Abstract 
Lectins belongs to diverse class of protein that binds to carbohydrate residues of the 
glycoproteins present on the cell surface. There are two interesting types of calcium 
dependent lectin i.e., Mannose-binding lectin (MBL) and DC SIGN which are involved in 
various infectious processes and in the regulation of the immune response. MBL is a serum 
protein which activates the lectin complement pathway upon binding with the glycan 
epitopes on the surface of pathogens or altered self-cell. High level of complement pathway 





Figure 15. Binding affinity of LPG- and hPG- based carbohydrates for A) MBL and B) 
DC-SIGN dimer. Author’s contributions: In this manuscript the author contributed to the 














Linear	 and	 hyperbanched	 polyglycerol	 based	 mannosides	 and	
fucosyllactosides	 were	 developed	 as	 nanomolar	 binders	 of	
Mannose	 binding	 lectin	 (MBL)	 and	 DC-SIGN	 using	 Label	 free	
microscale	thermophoresis	(MST)	and	surface	plasmon	resonance	
(SPR)	techniques,	respectively.	While	there	was	a	small	preference	
for	 hyperbranched	 polyglycerol	 in	 the	 case	 of	 MBL	 inhibitors,	 a	
clear	 advantage	 of	 ligand	 presentation	 on	 linear	 polyglycerol	
scaffolds	for	DC-SIGN	was	observed.	
Lectins	 are	 ubiquitous	 carbohydrate	 binding	 proteins[2]	 which	
are	 involved	 in	 many	 biological	 processes,	 including	 cell	
signalling,	 cell	 -	 cell	 interaction,	 and	 the	 immune	 response	 to	
pathogens.[3]	 C-	 type	 animal	 lectins	 are	 the	 largest	 and	most	
distinct	amongst	lectin	families.[4]	They	have	conserved	motifs	
in	carbohydrate	recognition	domain	(CRD)	that	bind	sugars	in	a	
Ca2+	 dependent	 manner.[3b,	 5]	 Soluble	 C-type	 lectins	 can	
recognize	 glycan	 epitopes	 on	 the	 surface	 of	 pathogens	 and	
thereby	tag	invaders	for	a	further	immune	response.	A	function	
of	 immune	 cell	 bound	 C-type	 lectins	 is	 the	 direct	 pathogen	
recognition.[6]	Mannose	binding	lectin	(MBL)	is	a	soluble	calcium	
dependent	 serum	 protein.[7]	 An	 intrinsically	 coiled-coil	 region	
which	 trimerizes	 the	 protein	 and	 a	 collagen-like	 domain	 are	
responsible	 to	 generate	 various	 oligomeric	 forms	 including	
dimers,	 trimers,	 tetramers,	 pentamers,	 and	 hexamers.[8]	MBL	
binds	to	the	sugar	residues	e.g.,	mannose,	fucose,	glucose,	N-
acetyl-D-glucosamine	 and	 N-acetyl-mannosamine	 on	 the	
surface	of	various	pathogens	e.g.,	viruses,	bacteria,	 fungi,	and	
parasites.[9]	 Agglutination	 of	 these	 microbes	 mediated	 by	
oligomeric	 MBL	 allows	 the	 clearance	 of	 pathogens	 through	
phagocytosis.[10]	Binding	of	MBL	to	pathogens	also	activates	the	
lectin	 pathway	 of	 the	 complement	 system.	 Consequently,	 a	
cascade	of	specific	proteolytic	events	generates	active	proteins	
that	 contribute	 to	 pathogen	 elimination	 and	 includes	 the	
generation	of	pro-inflammatory	stimuli	to	recruit	leukocytes.[8a]	
On	the	contrary,	a	high	level	of	complement	activity	has	been	
associated	 with	 chronic	 inflammatory	 diseases,	 transplant	
rejections,	 and	 diabetic	 nephropathy.[11]	 The	 complement	
system	 might	 play	 an	 important	 role	 in	 tissue	 damage	 and	
impaired	organ	function	after	ischemia-reperfusion	(IR).	In	the	
case	 of	 IR,	 MBL	 deposition	 on	 autologous	 cells	 has	 been	
observed	 which	 results	 in	 cell	 clearance,	 enhanced	 vascular	
permeability,	 blood	 clotting,	 and	 increased	 inflammation.[12]	
Thus,	 developing	MBL	 inhibitors	 to	 dampen	 the	 complement	
activity	on	demand	is	desirable.		
Dendritic	 Cell-Specific	 Intercellular	 adhesion	 molecule-3-
Grabbing	Non-integrin	(DC-SIGN)	is	a	type	II	trans-membrane	C-
type	 lectin	 which	 is	 involved	 in	 the	 recognition	 of	
oligosaccharides	 on	 the	 surface	 of	 viruses	 (e.g.,	 HIV,	 Ebola),	
fungi	 (e.g.,	 Candida	 albicans,	 A.	 fumigatus),	 bacteria	 (M.	
tuberculosis,	S.	pneumonia)	and	parasites	(Leishmania).[13]	DC-
SIGN	binds	to	highly	mannosylated	glycans	which	are	presents	
on	 several	 pathogens	 including	 HIV-1.[14]	 It	 also	 binds	 to	
fucosyllated	 glycans	 such	 as	 Lewis	 oligosaccharides.[15]	
Interestingly,	MBL	can	also	bind	with	gp120	on	HIV	virions	and	
can	block	their	entry	by	DC-SIGN.[16]		
Multivalent	 ligand	 presentation	 is	 effective	 for	 converting	
inhibitors	of	low	affinity	(Kd,affinity	~	mM–	µM)	to	the	ones	of	with	
high	 avidity	 (Kd,avidity	 ~	 nM).
[17]	 The	 binding	 affinity	 (Kd)	 of	
mannose	 binding	 lectin	 (MBL)	 to	mannose	 as	 determined	 by	
NMR	titration	was	~	3	mM	and	thus	can	be	improved	by	design	
of	multivalent	inhibitors.[1]	To	the	best	of	our	knowledge,	only	
Simoni	 and	 coworkers	 have	 reported	 the	 multivalent	
mannosylated	 glycodendrimers	 for	 the	 inhibition	 of	 MBL	















On	 the	other	 hand,	 several	 dendritic	multivalent	 inhibitors	 of	
DC-SIGN	have	been	reported	and	only	one	report	on	using	linear	
polymer	 scaffold	 has	 been	 published	 by	 Becer	 et.	 al.[21]	 In	 all	




Linear	 and	 hyperbranched	 polyglycerols	 are	 water	 soluble,	
biocompatible,	 and	 easily	 functionalizable	 polymer	 scaffolds.	
Recently	 we	 have	 compared	 linear	 and	 hyperbranched	
polyglycerol	 based	 multivalent	 sialosides	 for	 influenza	 virus	
binding.[22]	In	this	manuscript,	we	report	the	synthesis	of	linear	
and	 hyperbranched	 polyglycerols	 based	 multivalent	
mannosides	 and	 fucosyllactosides	 where	 the	 carbohydrate	
residues	 are	 present	 on	 different	 polymer	 backbones	 with	
varying	 ligand	 densities	 in	 a	 multivalent	 fashion.	 These	
synthesized	multivalent	glycosides	have	been	evaluated	for	the	
binding	 with	 MBL	 and	 DC-SIGN	 using	 microscale	









kDa	 hyperbranched	 polyglycerol[25]	 (hPG10OH	 5)	 were	
propargylated	using	propargyl	bromide	as	described	below.	The	
propargylated	 polyglycerols	 were	 coupled	 with	 2-Azido	
mannose	 derivative	 and	 2'-fucosyllactose	 azide	 using	 CuI-
catalyzed	 Huisgen	 click	 chemistry	 to	 obtain	 two	 different		
degrees	 of	 functionalization	 (DF)	 affording	 multivalent	
glycosides	LPG8Man	3a-b	(DF	=	0.40	and	1.00),	LPG8FL	4a-b	(DF	
=	 0.40	 and	 1.00),	 hPG10Man	 7a-b	 (DF	 =	 0.70	 and	 1.00)	 and	
hPG10FL	8a-b	(DF	=	0.60	and	1.00)	(Scheme	2).	All	intermediates	
and	 final	 products	 were	 characterized	 by	 spectroscopic	




Size	 distribution	 profiles	 of	 all	 glycosides	 and	 the	 parent	
polyglycerol	 polymers	 were	 determined	 by	 dynamic	 light	
scattering	(DLS)	technique	in	phosphate	buffer	saline	(PBS,	pH	
7.4)	at	a	concentration	of	1	mg/mL	(Table	1).	The	hydrodynamic	
diameter	 (Dh)	 for	 LPG8OH	1	was	 similar	 to	hPG10OH	5.
[26]	 This	
shows	 that	 the	used	LPG	and	hPG	scaffolds	are	equal	 in	 their	
size.	 However,	 it	 should	 be	 noted	 that	 the	 LPG	 had	 a	 lower	
molecular	weight	(8	kDa)	as	compared	to	the	dendritic	analogue	
(10	 kDa),	 which	 explains	 the	 increased	 swelling	 of	 the	 linear	
































the	observed	Dh	 values	 in	volume	distribution	profiles	 (Figure	
1).	 An	 increase	 in	 Dh	 was	 observed	 with	 increasing	 glycoside	
residue	 density	 for	 both	 the	 LPG	 and	 hPG	 based	 polymer	
backbones.	However,	increase	in	size	was	slightly	more	for	the	
fucosyllactoside	 derivatives	 than	 the	 mannoside	 derivatives	
(Table	1).				
All	 synthesized	 multivalent	 constructs	 and	 the	 non-
functionalized	polymer	were	assessed	for	their	binding	affinity	
against	 Mannose	 binding	 Lectin	 (MBL)	 and	 DC-SIGN	 using	








Figure	 1.	 Size	 analysis	 of	 the	 linear	 and	 hyperbranched	 polyglycerol	 based	
glycoconjugates	 by	 DLS.	 The	 volume	 distribution	 profiles	 of	 A)	 linear	 polyglycerol	
(LPG8OH	 1),	 linear	 polyglycerol	 mannosides	 (3a-b)	 and	 linear	 polyglycerol	











MST	 is	 a	 powerful	 technique	 to	 study	 the	 quantitative	
interaction	 between	 the	 biomolecules	 and	 small	 ligands	with	
very	 low	 sample	 consumption.[27]	 Label-free	 MST	 technique	







residues	 in	 the	 protein.	 Then	 the	 synthesized	 multivalent	





ligand	 density	 of	 1	 ligand/nm2.	 The	 hyperbranched	
glycopolymers	 i.e.	 hPG10Man	 (7a-b)	 and	 hPG10FL	 (3a-b)	 has	
affinity	 in	 the	 low	 micromolar	 range	 i.e.	 0.15	 –	 0.30	 µM.	
Interestingly	we	observed	 that	 the	 affinity	was	 nearly	 0.2-0.3	
µM	 for	 the	 constructs	 with	 the	 ligand	 density	 approaching	 1	
ligand/nm2.	 This	 also	 means	 that	 the	 fully	 functionalized	
multivalent	 mannosides	 and	 fucosyllactosides	 were	 more	
potent	 than	 the	 partially	 functionalized	 ones.	 The	 parent	
nonfunctionalized	 LPG8OH	 1	 and	 hPG10OH	 5	 did	 not	
substantially	bind	with	the	MBL.	Mannan	(from	Saccharomyces	






















with	 DC-SIGN	 were	 determined	 by	 SPR	 technique.	
Glycoconjugates	were	used	as	analyte	and	flowed	over	protein	
A	 sensor	 chip	 immobilised	 with	 DC-SIGN.	 The	 dissociation	
constant	at	equilibrium	was	evaluated	from	single	cycle	kinetics	
measurement	 of	 individual	 polymer.	 No	 big	 difference	 in	
binding	 affinities	 was	 observed	 for	 the	 low	 and	 high	 ligand	
density	 on	 linear	 polyglycerol	 mannoside	 or	 fucosyllactoside	
conjugates.	Binding	affinities	of	all	the	constructs	were	less	than	




µM)	 bound	 approximately	 five	 times	 more	 strongly	 than	
hPG10FL1.0	 8b	 (Kd	 =	 3.14	 µM).	 Thus,	 the	 influence	 of	 ligand	


































LPG8OH	1	 -	 -	 6.2±0.3	 0.30	 -	 No	binding	 No	binding	
LPG8Man0.40	3a	 39	 36	 6.4±0.4	 0.46	 0.32	 0.78±0.3	 0.31	
LPG8Man1.0	3b	 108	 100	 8.4±0.3	 0.41	 0.90	 0.19±0.1	 0.16	
lPG8FL0.40	4a	 42	 39	 8.2±1.3	 											0.60	 0.35	 0.62±0.3	 0.55	
lPG8FL1.0	4b	 108	 100	 9.1±1.0	 0.40	 0.90	 0.28±0.1	 0.44	
hPG10OH	5	 -	 	 6.3±0.5	 0.31	 -	 No	binding	 -	
hPG10Man0.70	7a	 92	 68	 8.2±0.3	 0.30	 0.74	 0.23±0.1	 0.27	
hPG10Man1.0	7b	 135	 100	 9.1±1.0	 0.57	 1.08	 0.15±0.1	 2.38	
hPG10FL0.60	8a	 81	 60	 9.4±0.3	 0.44	 0.64	 0.32±0.2	 0.64	
hPG10FL1.0	8b	 135	 100	 11.1±0.5	 0.58	 1.08	 0.27±0.1	 3.14	
Man-9-Glycan	 -	 -	 -	 -	 	 -	 0.01	
Mannan	 -	 -	 -	 -	 	 9.51±14.8	 	



























and	 hyperbranched	 PG	 glycoconjugates	 revealed	 a	 clear	
advantage	of	high	ligand	density	for	MBL	binding	and	the	ligand	
presentation	 on	 LPG	 scaffold	 for	 DC-SIGN	 binding.	While	 the	
hyperbranched	PG	based	hPG10Man1.0	7b	 appeared	 to	be	 the	
most	potent	candidate	against	MBL	with	Kd	of	152	nM,	against	
DC-SIGN	 was	 the	 LPG8Man1.0	 3b	 with	 Kd	 of	 157	 nM	which	 is	
approximately	 23,000-fold	 more	 active	 than	 the	 monovalent	
mannose	(Kd	=	3.5	mM).	Overall,	PG	based	glycoconjugates	are	
worth	exploring	for	MBL	and	DC-SIGN	binding	inhibition.	Such	
glycoconjugates	 will	 be	 effective	 for	 drug	 design,	 drug	
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1 Material and methods 
 
All the reagents and solvents were purchased from commercial suppliers and used 
without further purification unless stated otherwise. Reactions requiring dry or oxygen-
free conditions were carried out under argon in Schlenk glassware.  NMR spectra were 
recorded on JEOL ECP500, BRUKER AV500 and BRUKER AV700 spectrometers at 
400 MHz, 500 MHz and 700 MHz for 1H NMR spectra and 125 MHz and 175 MHz for 
13C NMR spectra, respectively. Chemical shifts are given in parts per million (ppm) in 
relation to deuterated solvent peak calibration. Infrared (IR) spectra were recorded with 
a Nicolet AVATAR 320 FT-IR 5 SXC (Thermo Fisher Scientific, Waltham, MA, USA) 
with a DTGS detector from 4000 to 650 cm-1. A TSQ 7000 (Finnigan Mat) instrument 
was used for ESI measurements and a JEOL JMS-SX- 102A spectrometer was used for 
the high-resolution mass spectra.  
DLS measurements of the various polymers were conducted by using a Nano DLS 
particle sizer (Brookhaven Instruments Corp.) at 25 oC. Aqueous samples were filtered 
through 0.2 mm filters prior to analysis. Water of Millipore quality was used in all 
experiments.  
NS0-derived recombinant human DC-SIGN/CD209 Fc Chimera Protein, CF and 
HEK293-derived recombinant human MBL Protein, CF were purchased as dimers from 
R & D Systems Biotechnology company, US. 2'-Fucosyllactose was purchased from 
Carbosynth. 2-Azidoethyl-2,3,4,6-tetra-O-acetyl-alpha-D-mannopyranoside was 
purchased from Apollo scientific. 
 
2 Label-free microscale thermophoresis (MST) 
 
Label-free microscale thermophoresis was used to measure the binding interactions 
between MBL and PG based glycoconjugates according to the following protocol. For 
each measurement, a dilution series with constant MBL concentration but varying 
ligand concentrations was prepared in PBS++. No significant ligand-derived 
autofluorescence was detected at 280 nm wavelength. The final MBL concentration was 
100 µM. All measurements were performed at 22 °C. The thermophoretic movement of 
fluorescent MBL was monitored with a laser on for 30 s and off for 5 s keeping the MST 
power at 20% and LED power at 20%. Fluorescence was measured before laser heating 




from three independent thermophoresis measurements using the NanoTemper software 
(NanoTemper Technologies, Munich, Germany). 
 
3 Surface Plasmon Resonance (SPR) 
 
Experiments were performed on a Biacore X100 instrument (GE Healthcare Europe, 
Freiburg, Germany) at 25 °C, using HBS-Ca-Mn buffer (10 mM HEPES, pH 7.4, 150 
mM NaCl, 0.1 mM CaCl2 and 0.01 mM MnCl2) in all cases. DC-SIGN, Fc Chimera 
Protein (R & D Systems Biotechnology company, US) was immobilised on a protein A 
sensor chip (GE Healthcare, final response 1700 RU), whereas the reference lane was 
left unfunctionalized. Each cycle consisted of a 120 s period of sample contact time 
(association phase) followed by a 600 s dissociation phase. All sample measurements 
were analysed with single cycle kinetics. Therefore, a concentration series of each 
sample was measured in triplicates. The determination of Kd values was performed with 
response unit (RU) data points taken at 15 s before injection stop using built-in software 
of the Biacore X100. Corresponding binding isotherms were plotted. 
 




2'-Fucosyllactose azide  
 
2'-Fucosyllactose (0.07 g, 0.143 mmol) was dissolved in deuterium oxide (1 mL). 
Diisopropylethylamine (0.25 ml, 1.43 mmol), NaN3 (0.092 g, 1.73 mmol) and DMC 
(0.071 g, 0.43 mmol) were added to the above mixture and the reaction mixture was 
stirred for 1 h at 0 oC. After 1 h, the solvent was evaporated under high vacuum, DMF 
was added and it was centrifuged, and supernatant was collected. This centrifugation 
step was repeated 3-4 times and all the supernatant were collected and concentrated in 
vacuo. It was then dissolved in water and passed through pre-neutralized resin column 
(Dowex H). All the fraction was collected and dialysed in water to give the pure product. 
(0.071g, 0.139 mmol, Yield = 97.41 %). 1H NMR (500 MHz, D2O): δ = 5.30 (d, J = 
2.95 Hz, 1H, H-1'), 4.85 - 4.83 (1H, m), 4.64 (d, J = 7.55 Hz, 1H, H-1'), 4.31 (quart, J = 
6.4 Hz, 1H, H-4''), 4.09 - 3.66 (m, 14H), 3.43 (t, J = 8.8 Hz, 1H, H-2), 1.32 (d, J = 6.15 
Hz, 3H, -CH3); 13C NMR (125 MHz, D2O ): δ = 100.4, 99.6, 90.2, 77.4, 76.5, 75.4, 
74.5, 73.8, 72.8, 71.9, 69.8, 69.3, 68.4, 67.1, 61.3, 60.2, 15.5; IR (film): ν = 3368.07, 








Dried LPG (0.200 g, 1.08 mmol OH to be functionalized) was dissolved in dry DMF 
(10 mL) and cooled to 0 °C. To the stirred solution of LPG in dry DMF at 0 oC, NaH 
(0.054 g, 2.15 mmol, 2 eq., 95%) was added. After addition ice bath was removed and 
the reaction mixture was allowed to stir at room temperature for 3 hours and cooled 
down again to 0 oC. The propargyl bromide (0.278 mL, 3.22 mmol, 3 eq.) in dry DMF 
(1 mL) was added slowly to the reaction mixture and stirred at room temperature 
overnight. The excess of NaH was quenched by the dropwise addition of water while 
keeping the reaction flask in an ice bath. The DMF was removed under reduced pressure 
and the resulting mixture was dialyzed in MeOH to afford LPG-propargyl (0.180 g, 
0.018 mmol, Yield = 73.17 %). Degree of propargylation was quantified by 1H NMR, 
DF = 0.40. 1H NMR (500 MHz, CD3OD): δ = 4.22 (s, 2H, OCH2C≡CH), 3.71 - 3.55 
(m, 13H, LPG backbone), 2.90 (s, 1H, C≡CH); 13C NMR (125 MHz, CD3OD): δ = 
81.57, 80.90, 80.01, 76.33, 70.88, 62.79, 59.43; IR (film): ν = 3397.96, 3281.29, 
2917.77, 2874.38, 2113.6, 1713.3, 1644.98, 1460.81, 1352.82, 1072.23 cm-1. 
 
LPG8propargyl1.00 2b  
 
Similar procedure as for 2a: LPG (0.235 g, 3.17 mmol OH to be functionalized) was 
propargylated using NaH (0.16 g, 6.35 mmol, 2 eq., 95%) and propargyl bromide (0.081 
mL, 9.52 mmol, 3.0 eq.). DF = 1.00. (0.231 g, 0.0194 mmol, Yield = 66.57 %). 1H NMR 
(500 MHz, CD3OD): 1H NMR (500 MHz, CDCl3): δ = 4.18 (s, 2H, OCH2C≡CH), 3.65 
- 3.57 (m, 5H, LPG backbone), 2.48 (s, 1H, C≡CH); 13C NMR (125 MHz, CDCl3): δ = 
79.99, 78.70, 74.80, 69.87, 58.66; IR (film): ν = 3285.14, 2919.7, 2114.58, 1357.64, 
1033.66 , 952.66. 
 
hPG10Propargyl0.60 6a  
Similar procedure as for 2a: hPG (0.198 g, 1.60 mmol OH to be functionalized) was 
propargylated using NaH (0.081 g, 3.2 mmol, 2 eq., 95%) and propargyl bromide 
(0.0.413 mL, 4.8 mmol, 3.0 eq.). DF = 0.60 (0.190 g, 0.0145 mmol, Yield: 73.64 %). 
1H NMR (500 MHz, CD3OD): δ = 4.36 (s, 1H, sec OCH2C≡CH), 4.23 (s, 1H, primary 
OCH2C≡CH), 3.89 - 3.60 (m, 8H, hPG backbone), 2.91 (s, 1H, C≡CH); 13C NMR (125 
MHz, CD3OD) : δ = 81.51, 79.95, 78.08, 76.43, 74.05, 72.45, 71.21, 70.74, 59.48, 





hPG10Propargyl1.00 6b  
Similar procedure as for 2a: hPG (0.227 g, 3.06 mmol OH to be functionalized) was 
propargylated using NaH (0.155 g, 6.13 mmol, 2 eq., 95%) and propargyl bromide 
(0.078 mL, 9.19 mmol, 3.0 eq.). DF = 1.00. (0.259 g, 0.017 mmol, Yield: 75.51 %). 1H 
NMR (500 MHz, CD3COCD3): δ = 4.37 (s, 1H, sec OCH2C≡CH), 4.23 (s, 1H, primary 
OCH2C≡CH), 3.87 - 3.60 (m, 5H, hPG backbone), 2.97 (brs, 1H, C≡CH); 13C NMR 
(125 MHz, CD3COCD3) : δ = 80.75, 80.17, 78.70, 76.58, 74.97, 71.35, 69.82, 58.23, 
57.23, 29.02; IR (film): ν = 3287.07, 2868.59, 2114..56, 1033.66 cm-1. 
 
LPG8Man0.40 3a 
To a mixture of LPG8Propargyl0.40 2a (0.023 g, 0.101 mmol of propargyl to be 
functionalized) and azido mannose (0.0465 g, 0.112 mmol) in DMF (15 mL), 
CuSO4.5H2O (0.005 g, 0.02 mmol) and sodium ascorbate (0.040 g, 0.203 mmol) 
solution in H2O (2 mL) were added dropwise. The reaction mixture was degassed 
thoroughly with argon for 5-10 minutes and then allowed to stir for 2 days at 40 oC. The 
reaction was stopped, and solvent was removed under reduced pressure. 2M NaOH (7 
mL) was added to the residue and stirred at room temperature for 4-5 hrs. The reaction 
mixture was neutralized by adding 2M HCl solution and dialyzed first against water and 
aqueous EDTA solution for 2 days and again using only water for 4 days. The solvent 
of the dialysis was changed thrice a day. The aqueous solution obtained after dialysis 
was lyophilized to afford LPG8 Man0.40. DF = 0.36. (0.046 mg, 0.002 mmol, Yield: 
93.91%). DF = 0.36. 1H NMR (500 MHz, D2O): δ = 8.10 (s, 1H, C=CH), 4.64 (brs, 4H, 
CH2CH2Trz, TrzCH2O), 4.04 – 3.52 (m, 22H, Man: H-1, H-2, H-3, H-4, H-5, H-6, 
CHHaCH2Trz, LPG backbone) 3.02 (s, 1H, CHHbCH2Trz); Elemental analysis: calcd 
(%): N 7.83%; found: N 6.36 %. 
 
LPG8Man1.00 3b  
Similar procedure as for 3a: LPG8Propargyl1.00 2b (0.020 g, 0.141 mmol of propargyl 
to be functionalized) and azido mannose (0.107 g, 0.257 mmol) were coupled using 
CuSO4.5H2O (0.008 g, 0.034 mmol) and sodium ascorbate (0.068 g, 0.342 mmol) 
assisted click reaction. Deprotection was performed by similar procedure as 3a using 




(700 MHz, D2O): δ = 8.13 (s, 1H, C=CH), 4.65 (brs, 4H, CH2CH2Trz, TrzCH2O), 4.10 
– 3.61 (m, 13H, Man: H-1, H-2, H-3, H-4, H-5, H-6, CHHaCH2Trz, LPG backbone), 
3.11 (s, 1H, CHHbCH2Trz); Elemental analysis: calcd (%): N 10.23%; found: N 9.24 %. 
 
LPG8FL0.40 4a  
Similar procedure as for 3a: LPG8Propargyl0.40 (0.020 g, 0.089 mmol of propargyl to be 
functionalized) and 2'-fucosyllactose azide (0.054 g, 0.106 mmol) were coupled using 
CuSO4.5H2O (0.004 g, 0.178 mmol) and sodium ascorbate (0.035 g, 0.178 mmol) 
assisted click reaction. (0.048 g, 0.014 mmol, Yield: 72.72 %). DF = 0.39. DF = 0.39. 
1H NMR (700 MHz, D2O): δ = 8.31 (s, 1H, C=CH), 5.80 (s, 1H, H-1), 5.35 (s, 1H, H-
1''), 4.72 (brs, 2H, CH2Trz), 4.61 (d, J = 7 Hz, 1H, H-1'), 4.26 (s, 1H, H-4''),  4.09 - 3.73 
(m, 28H, FL: H-2, H-3, H-4, H-5, H-6, H-2', H-3', H-4', H-5', H-6', H-2'', H-3'', H-5'', 




Similar procedure as for 3a: LPG8Propargyl1.00 (0.020 g, 0.171 mmol of propargyl to be 
functionalized) and 2'-fucosyllactose azide (0.105 g, 0.205 mmol) were coupled using 
CuSO4.5H2O (0.008 g, 0.034 mmol) and sodium ascorbate (0.068 g, 0.342 mmol) 
assisted click reaction. (0.091 g, 0.013 mmol, Yield: 75.20%). DF = 1.00. 1H NMR (700 
MHz, D2O): δ = 8.20 (s, 1H, C=CH), 5.70 (s, 1H, H-1), 5.26 (s, 1H, H-1''), 4.52 - 3.64 
( (m, 28H, FL: H-1, H-2, H-3, H-4, H-5, H-6, H-1', H-2', H-3', H-4', H-5', H-6', H-1'' H-
2'', H-3'', H-4'', H-5'', LPG backbone), 1.18 (s, 3H, CH3); Elemental analysis: calcd (%): 
N 6.27 %; found: N 5.45 %. 
 
hPG10Man0.70 7a 
Similar procedure as for 3a: hPG10Propargyl1.00 (0.020 g, 0.178 mmol of propargyl to 
be functionalized) and azidomannose (0.089 g, 0.214 mmol) were coupled using 
CuSO4.5H2O (0.008 g, 0.035mmol) and sodium ascorbate (0.070 g, 0.356 mmol) 
assisted click reaction. Deprotection was performed by similar procedure as 3a using 
2M NaOH. (0.051 g, 0.016 mmol, Yield: 69.86%). DF = 0.68. 1H NMR (700 MHz, 




16H, Man: H-1, H-2, H-3, H-4, H-5, H-6, CHHaCH2Trz, hPG backbone), 3.13 (s, 1H, 
CHHbCH2Trz Elemental analysis: calcd (%): N 9.29%; found: N 9.02 %. 
 
hPG10Man1.00 7b 
Similar procedure as for 3a: hPG10Propargyl1.00 (0.055 g, 0.495 mmol of propargyl to 
be functionalized) and azidomannose (0.0309 g, 0.743 mmol) were coupled using 
CuSO4.5H2O (0.025 g, 0.099 mmol) and sodium ascorbate (0.196 g, 0.99 mmol) assisted 
click reaction. Deprotection was performed by similar procedure as 3a using 2M NaOH. 
DF = 1.00. (0.155 g, 0.003 mmol, Yield: 77.6 %). 1H NMR (700 MHz, D2O): δ = 8.12 
(s, 1H, C=CH), 4.65 (brs, 4H, CH2CH2Trz, TrzCH2O), 4.10 – 3.87 (m, 13H, Man: H-1, 
H-2, H-3, H-4, H-5, H-6, CHHaCH2Trz, hPG backbone), 3.13 (s, 1H, CHHbCH2Trz); 
Elemental analysis: calcd (%): N 10.36%; found: N 10.78 %. 
 
hPG10FL0.60 8a 
Similar procedure as for 3a: hPG10Propargyl0.60 (0.020 g, 0.124 mmol of propargyl to 
be functionalized) and 2'-fucosyllactose azide (0.082 g, 0.161 mmol) were coupled 
using CuSO4.5H2O (0.006 g, 0.0.024 mmol) and sodium ascorbate (0.049 g, 0.248 
mmol) assisted click reaction. (0.0646 g, 0.001 mmol, Yield: 72.58 %). DF = 0.60. 1H 
NMR (700 MHz, D2O): δ = 8.21 (s, 1H, C=CH), 5.70 (s, 1H, H-1), 5.26 (s, 1H, H-1''), 
4.52 - 3.65 (m, 27H, CH2Trz , FL: H-2, H-3, H-4, H-5, H-6, H-1', H-2', H-3', H-4', H-
5', H-6', H-2'', H-3'', H-5'', H-5'', hPG backbone), 1.18 (s, 3H, CH3); Elemental analysis: 
calcd (%): N 5.84 %; found: N 6.21 %. 
 
hPG10FL1.00 8b 
Similar procedure as for 3a: hPG10Propargyl1.00 (0.015 g, 0.134 mmol of propargyl to 
be functionalized) and 2'-fucosyllactose azide (0.089 g, 0.173 mmol) were coupled 
using CuSO4.5H2O (0.006 g, 0.027 mmol) and sodium ascorbate (0.053 g, 0.267 mmol) 
assisted click reaction. DF = 1.00. (0.065 g, 0.0007 mmol, Yield: 73.03 %). 1H NMR 
(500 MHz, D2O): δ = 8.26 (s, 1H, C=CH), 5.77 (s, 1H, H-1), 5.34 (s, 1H, H-1''), 4.25 – 
3.73 (m, 27H, CH2Trz , FL: H-2, H-3, H-4, H-5, H-6, H-1', H-2', H-3', H-4', H-5', H-6', 
H-2'', H-3'', H-5'', H-5'', hPG backbone), 1.24 (s, 3H, CH3); Elemental analysis: calcd 





5 1H and 13C spectra of all the intermediates and final molecules. 

















































6. LPG8Man0.40 3a 
 
Fig. s6 1H spectra of compound 3a 
 








8. LPG8FL0.40 4a 
 
 
Fig. s8 1H spectra of 4a 
 
9. LPG8FL1.00 4b 
 
 




10. hPG10Man0.70 7a 
 
 
Fig. s10 1H spectra of compound 7a 
11. hPG10Man1.00 7b 
 
 
Fig. s11 1H spectra of compound 7b 







Fig. s12 1H spectra of compound 8a 
 
13. hPG10FL1.00 8b 
 








Fig. s14 Binding isotherm of compound 2a 
 
Fig. s15 Binding isotherm of compound 2b 
 





Fig. s15 Binding isotherm of compound 4b 
 
Fig. s16 Binding isotherm of compound 7a 
 
Fig. s17 Binding isotherm of compound 7b 
 
Fig. s18 Binding isotherm of compound 8a 
 
 





Fig. s20 Binding isotherm of compound Man9Glycan 
 
7.1 Gel permeation chromatography of hyperbranched and linear 
polyglycerol 
Mn = 10642 g/mol, Mw = 16633 g/mol, Mz = 24882 g/mol, D = 1.56 






















7.2 Gel permeation chromatography of linear polyglycerol 
 
Mn = 6530 g/mol, Mw = 9298 g/mol, Mz = 12589 g/mol, D = 1.42 








Summary and Conclusion 
 
5 Summary and conclusions 
In the first part of the thesis we designed inhibitors for influenza A virus X31 (subtype 
Aichi). We targeted hemagglutinin (HA) which exist in homotrimeric form on the lipid 
membrane of the virus. Three receptor binding sites are present on the HA trimer which 
recognizes sialic acid residues on the host cell and cause viral infection. For this purpose, I 
prepared a series of trivalent sialosides to target the HA trimer. I choose trivalent rigid and 
flexible scaffold to develop the inhibitor. The commercially available 4-
(((benzyloxy)carbonyl) amino)-4-(2-carboxyethly) heptanedioic acid abbreviated as Tris 
was used as flexible core and for rigid system, adamantane core was used. Flexible 
oligoethylene glycol (OEG) of different lengths were used as spacer because of their 
biocompatibility and hydrophilicity. As per the MD simulation data, OEG should consist of 
6-14 EG units to cover the distance between the center of scaffold to the ligand binding site 
on the HA.  
Each of the synthesized tripodal sialosides were tested against IAV-X31 in 
hemagglutination inhibition assay. Non-functionalized scaffolds were used as negative 
control and did not show any binding inhibition in HAI assay. The adamantane based 
trivalent sialoside with hexaethylene glycol spacer namely cbzAd(EG6SA)3 was the most 
potent compound with inhibition constant (Ki) in micromolar range. To test the dependence 
of binding affinity on the presence of 2 vs 3 ligand, the adamantane based divalent sialoside 
was also prepared and tested in HAI assay. The Ki values for the both trivalent and divalent 
sialosides in terms of tripod concentration were in micromolar range: 30 µM and 100 µM, 
respectively.  This difference between the Ki value could be assigned to cooperativity factor 
as discussed in the previous section (section 1.1). In contrast, the HAI value of flexible Tris 
based trivalent sialosides was in millimolar range and 6.7 mM was the lowest Ki value for 
the flexible core compound with tetra ethylene glycol spacer i.e., cbzTris(EG4SA)3.  
All these compounds when tested for their binding affinity against rhodamine labeled IAV 
using labelled MST technique, showed dissociation constant in 58 and 71 µM for trivalent 
and divalent adamantane based sialosides respectively. This was in good comparison with 
the HAI values. However, for the flexible core based trivalent sialosides the binding affinity 
was also in micromolar range (16 µM) for cbzTris(EG4SA)3. This could be attributed to 
non-specific binding of these compounds with the virus other than the HA which needs to 
be further investigated. In conclusion, rigid core adamantane based sialoside with EG6 
spacer was the most potent candidate among the series tripodal sialosides against IAV 
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which can be further used for the multimeric presentation of trivalent ligand on larger 
scaffolds to achieve high binding affinities against IAV. 
In the second project, an easy approach i.e., copper assisted click chemistry was used for 
the development of linear and hyperbranched polyglycerol based glycoarchitecture with 
varying degree of ligand densities and binding affinity was evaluated for lectin binding. 
Mannose (Man) and fucosyllactose (FL) azides were used to decorate these 
glycoarchitecture. The hydrodynamic diameter of these glycoconjugates was analyzed 
using dynamic light scattering (DLS) technique and size was in the range of 6-11 nm. We 
observed an increase in size as the ligand density increases. Two types of C-type lectin 
namely MBL and DC-SIGN was used for this purpose. 
All the synthesized PGs based mannosides and fucosyllactosides were tested for binding 
with rhMBL in a label-free MST technique where the intrinsic fluorescence of MBL protein 
due to tryptophan unit was utilized to analyze the molecular migration in the presence of 
applied temperature gradient. The dissociation constant of all the glycoconjugates was in 
low micromolar range. However, we observed a trend that the affinity was higher for high 
ligand density. With linear PG based mannosides and fucosyllactosides, the affinity 
increasesd 4 times and 2 times, respectively, with an increase in ligand densities (100% 
functionalization). In the case of hyperbranched PG based mannosides and 
fucosyllactosides, the binding affinity is still in low micromolar range, however, there was 
not any significant increase in binding affinity with increase of ligand densities. Non-
functionalized PG scaffolds were used as a negative control did not show any binding upto 
100 µM. 
Thus, we conclude that completely functionalized PGs scaffold with Man and FL showed 
to be potent binder for MBL in comparison to partially functionalized architecture. The 
most potent candidate against MBL was hPG10Man1.0 with Kd = 152 nM. 
Furthermore, the same set of compounds was also used to study the binding affinity of DC-
SIGN using surface plasmon resonance spectroscopy (SPR) based binding assay. In this 
study DC-SIGN was immobilized on the protein A sensor chip and glycoconjugates were 
flowed over the chip as analytes. This study showed that all the glycoconjugates binds to 
DC-SIGN with a binding affinity less than 1 µM. For LPG based glycoconjugate, there was 
not any big difference in Kd values with different degree of functionalization (DF). 
However, in the case of dendritic glycoconjugates the binding affinity was observed to 
decrease with increasing DF. Here also, unfunctionalized PG scaffold were tested for 
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negative control. Here, LPG8Man1.0 was the most potent candidate with a Kd value of 157 
nM which was approx. 23,000-fold higher affinity than mannose residue (Kd = 3.5 mM). 
In conclusion, these low molecular weights, PG based multivalent mannosides and 




























Design of trivalent sialosides with optimum linker length to target HA of influenza virus is 
a promising strategy for the development of anti-influenza agents. As described in this 
thesis, attaching sialic acid at the terminal position to block the receptor binding site of HA 
trimer which is present on the surface of influenza virus increases the binding potency in 
comparison to monovalent interaction of SA to HA. Trivalent sialosides prepared in this 
part have amino group functionality at the top of the core which can be exploited to attach 
the trivalent ligand system on the multivalent scaffold such as polyglycerols. This 
optimizing trivalent ligand for multi-trimeric presentation may afford high affinity inhibitor 
for IAV.  
Moreover, polyglycerol scaffolds were easily functionalized with the desired carbohydrates 
with varying degrees of functionalization shown in the second part of this thesis. When PGs 
were fully functionalized with Man and FL, the binding affinity was in nanomolar range 
with commercially available dimeric MBL and DC-SIGN. A study comparing native 
proteins will more interesting and might lead to even better binders than with the dimeric 
MBL and DC-SIGN.  Efficient binders of MBL and DC-SIGN will be of great therapeutic 
interest. These can further be investigated for MBL complement inhibition followed by 
other associated possible biomedical applications. Similarly, DC-SIGN binders can be 
explored for the pathogen-cell binding inhibition using HIV or Ebola virus particles in cell-
based assays.  
These multivalent glycoconjugates are of therapeutic interest in drug design and discovery 
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7 Abstract and Kurzzusammenfassung 
Abstract 
This thesis focused on the design, synthesis, and evaluation of multivalent glycoconjugates 
for lectin binding. The first part discusses the optimization of trivalent sialosides based on 
functionalizable rigid and flexible core having different lengths of polyethylene glycol 
spacer for targeting hemagglutinin trimeric (HA3) glycoproteins on the surface of influenza 
virus. All the synthesized compounds were screened using hemagglutination inhibition 
assay (HAI) and microscale thermophoresis (MST). The rigid adamantane-based trivalent 
sialosides with hexaethylene glycol (EG6) linker showed a binding affinity in low 
micromolar range with Ki = 30 µM.  
The second part of this thesis discusses the synthesis and evaluation of a series of 
polyglycerol based (linear and hyperbranched) mannosides and fucosyllactosides for C-type 
lectin binding. Polyglycerol polymers are highly water soluble, biocompatible, and easily 
functionalizable. Polyglycerol based multivalent glycoconjugates were synthesized using a 
copper assisted click reaction of azido fucosyllactoside and azido mannoside derivative 
with the propargylated polyglycerol with different degrees of functionalization. These 
glycoconjugates were tested for binding with mannose binding lectin (MBL) and DC-SIGN 
using biophysical techniques i.e., microscale thermophoresis (MST) and surface plasmon 
resonance (SPR), respectively. The most potent candidates for MBL and DC-SIGN binding 
were 100% functionalized hPG- and LPG- based mannosides, respectively, with the 
dissociation constant (Kd) in nanomolar range. Nanomolar binder for DC-SIGN was 
approximately 23,000-fold more active than the monovalent mannose with Kd of 3.5 mM. 
Further on, these multivalent architectures can further be investigated and optimized for the 













Der Fokus dieser Arbeit war das Design, die Synthese und die Evaluation von Lektin-
bindenden multivalenten Glykokonjugaten. 
Im ersten Teil wird die Optimierung von trivalenten Sialosiden auf der Basis von 
funktionalisierbaren starren oder flexiblen Kernen und verschieden langen 
Polyethylenglycol-Spacern für die Bindung an Hemagglutinin-Trimere (HA3) auf der 
Oberfläche von Influenzavirus diskutiert. Die Bindungseigenschaften der synthetisierten 
Verbindungen wurden mittels Hämagglutinations-Inhibitions-Assays (HAI) und 
Mikroskalenthermophorese (MST) analysiert. Die starren trivalenten Sialoside auf 
Adamantan-Basis mit Hexaethylenglykol (EG6)-Linker eine zeigten Bindungsaffinität im 
niedrigen mikromolaren Bereich mit einer Bindungskonstante (Ki) von 30 µM. 
Der zweite Teil dieser Arbeit befasst sich mit der Synthese und Bewertung einer Reihe von 
linearen und hyperverzweigten Mannosiden auf Polyglycerin-Basis und Fucosyllactosiden 
für die Bindung von Lektinen vom C-Typ. Polyglycerin-basierte Polymere sind 
wasserlöslich, biokompatibel und leicht funktionalisierbar. Mehrwertige Glykokonjugate 
auf Polyglycerinbasis wurden unter Verwendung einer kupferassistierten Klickreaktion 
ausgehend von Azidofucosyllactosid und Azidomannosidderivaten mit propargylierten 
Polyglycerol mit unterschiedlichem Funktionalisierungsgrad synthetisiert. Diese 
Glykokonjugate wurden auf Bindung mit Mannose-bindendem Lektin (MBL) und DC-
SIGN unter Verwendung biophysikalischer Techniken wie Mikroskalenthermophorese 
(MST) bzw. Oberflächenplasmonresonanz (SPR) untersucht. Die aussichtsreichsten 
Kandidaten für die MBL- und DC-SIGN-Bindung waren vollständig funktionalisierte 
Mannoside auf hPG und lPG Basis mit Dissoziationskonstanten (Kd) im nanomolaren 
Bereich. Der beste Kandidat für die DC-SIGN Bindung war mit einem Kd von 3,5 µM etwa 
23.000-fach aktiver als monovalente Mannose. Die synthetisierten multivalenten 
Architekturen kommen daher für eine zukünftige therapeutische Anwendung in Frage und 
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9.1 List of abbreviations 
AGE  Allyl glycidyl ether 
Approx. Approximately 
Arg  Arginine 
Me methyl  
MeOH methanol 
min(s)  minute(s) 
NMR Nuclear Magnetic Resonance 
ConA  Concavallin A 
CTL  C-type lectins 
Cryo TEM Cryo transmission electron microscopy 
CT  Cholera toxin 
C1-INH C1 esterase inhibitor 
CTLD  C-type lectin like domain 
CRP  C-reactive protein 
CRD  Carbohydrate recognition domain 
DB  Degree of branching 
DC-SIGN Dendritic cell-specific ICAM-3-grabbing non-integrin  
DF   Degree of functionalization 
DLS  Dynamic light scattering 
DNA  Deoxy ribose nucleic acid 
dPG  Dendritic polyglycerol 
E. COLI Escherichia Coli 
EEGE  Ethoxyethyl glycidyl ether 
EM  Effective molarity 
HA   Hemagglutinin 
HA3  Hemagglutinin trimer 
HIV  Human immunodeficiency virus 
hMBL  Human Mannose binding lectin 
HSV  Herpes simplex virus 
IAV  Influenza A virus 
ICAM-1 Intracellular adhesion molecule-1 




ITC  Isothermal titration calorimetry 
Kd  Dissociation constant 
lPG  Linear polyglycerol 
mAbs  Monoclonal antibody 
MASP  Mannan-binding lectin- associated serine protease 
Map19  MBL-associated protein of 19 kDa 
MD  Molecular dynamics 
MBP  Mannose binding protein 
MST  Microscale thermophoresis 
M.Wt  Molecular weight 
mRNA Messenger ribose nucleic acid 
NA  Neraminidase 
NAI  Nuraminidase inhibitor 
OEG  Oligoethylene glycol 
PAMAM Poly(amido-amine) 
PAA  Polyacrylamide 
PDI  Polydispersity index 
PPOK  Potassium 3-phenylpropanolate 
nPG  Polyglycerol based nanogel 
PPOK  potassium 3-phenylpropanolate  
PPE  Poly(p-phenylene ethynylene) 
PPI  Poly(ethylenimine) 
PLL  Poly-L-lysine 
PEG  Polyethylene glycol 
RBC  Red blood cell 
rhMBL Recombinant human MBL 
RNA  Ribose nucleic acid 
ROMP  Ring opening metathesis polymerization 
ROMBP Ring-opening metathesis polymerization 
SiRNA Small interfering RNA 
SA  Sialic acid 
SCVP  Self-condensing vinyl polymerization 
sLex   Sialylated LewisX 




sCR1  Soluble complement receptor type-1 
SPR   Surface plasmon resonance 
tBGE  tert-butyl glycidyl ether 
TBI  Traumatic brain injury 
TCC  Terminal complement complex 
NOct4Br Tetraoctylammoniumbromid  
iBu3Al  Triisobutylaluminum  
TMP  Trimethylolpropane 
TMSGE Trimethylsilyl glycidyl ether 
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